Horizon2020 SC1 – Health, Demographic change and Wellbeing - Opportunità per l’area “Salute (2018-2020)”

Horizon 2020

Punto di Contatto Nazionale SC1

Caterina BUONOCORE

buonocore@apre.it

Servizi APRE Informazioni sui topics Pre-screening delle proposte Incontro con coordinatori selezionati per il 2° stage Corsi di formazione, webinars Apre weekly, Apre live, APRE magazine, sito web, FP 9

Servizi HNN2.0 http://www.healthncp.net/

Webinars ricerca partner attraverso gli ncp Eventi di creazione di partnerships Eventi rilevanti e conferenze tematiche Bandi per il settore health Eranets per il settore health

Servizi Access4SMEs

è adesso disponibile EIC SME Instrument annotated template<http://www.access4smes.eu/2018/01/09/the-annotated-proposal-template-sme-instrument/> La guida è stata prodotta da Access4SMEs<http://www.access4smes.eu/>, la rete europea dei National Contact Point PMI e Accesso alla finanza

2

3

http://www.apre.it/media/459686/apre_panoramica_partecipazione_h2020.pdf

Bandi SC1 - 2014-2015-2016-2017

No. topics Budget Mill. EUR

Proposte presentate Proposte finanziate Tasso di successo

62 2939,3 3373 343 10%

No. Partecipanti italiani in proposte presentate

No. Partecipanti italiani finanziati

Tasso di successo partecipanti Italiani

3716 369 9,9%

No. Proposte presentate a coordinamento italiano

No. Coordinamenti italiani finanziati

Tasso di successo coordinatori Italiani

459 (13% del totale EU) 26 5,6%

Partecipazione

Coordinamento

Source:

http://ec.europa.eu/research/horizon2020

Le opportunità per il settore health

Health Research opportunities around H2020

Excellent Science

European Research Council

Frontier research by the best individual teams

Future and Emerging Technologies

Collaborative research to open new fields of innovation

Marie Skłodowska Curie actions

Opportunities for training and career development

Research infrastructures (including e-infrastructure)

Ensuring access to world-class facilities

Industrial Technologies

Leadership in enabling and industrial technologies

ICT, nanotechnologies, materials, biotechnology, manufacturing, space

Access to risk finance

Leveraging private finance and venture capital for research and innovation

Innovation in SMEs

Fostering all forms of innovation in all types of SMEs

Societal Challenges

Health, demographic change and wellbeing

Food security, sustainable agriculture, marine and maritime research & the bioeconomy

Secure, clean and efficient energy

Smart, green and integrated transport

Climate action, resource efficiency and raw materials

Inclusive, innovative and reflective societies

Secure societies

European Institute of Innovation and Technology (EIT)

Spreading Excellence and Widening Participation

Science with and for society

Joint Research Center (JRC) 6

Health in H2020

Health solutions can imply different phases of research and innovation

7 INNOVATION

RESEARCH

INDUSTRIAL LEADERSHIP

2° PILLAR

8

Connections to Health in Pillar II

ICT ICT for health

Nano-technology

Nano for

health

Materials Materials

for health

Biotech Red

Biotech

Industrial Technologies

Leadership in enabling and industrial technologies

ICT, nanotechnologies, materials, biotechnology, manufacturing, space

Access to risk finance

Leveraging private finance and venture capital for research and innovation

Innovation in SMEs

Fostering all forms of innovation in all types of SMEs

HEALTH

SOCIETAL CHALLENGES (PILLAR III)

3° PILLAR

10

HEALTH implications in Societal Challenges

HEALTH

Management

of crisis

Societal Challenges

Health, demographic change and wellbeing

Food security, sustainable agriculture, marine and maritime research & the bioeconomy

Secure, clean and efficient energy

Smart, green and integrated transport

Climate action, resource efficiency and raw materials

Inclusive, innovative and reflective societies

Security society

ICT for

Health

Efficient

Building /

Hospitals Nutrition

and Health

Environment

and Health

Security of

Health data

SC1. HEALTH,

DEMOGRAPHIC

CHANGE

AND

WELLBEING

12

Programmazione dei prossimi 3 anni di H2020

SC1 2018-2020

Nuova struttura del WP SC 1 2018-2020

Call 1. Better health and care, economic growth and sustainable health systems (RTD)

1.1 Personalised medicine 1.2 Innovative health and care industry 1.3 Infectious diseases and improving global health 1.4 Innovative health and care systems – Integration of care 1.5 Decoding the role of the environment for health and well-being

Call 2. Digital Transformation in Health and Care (CNECT) Call 3. Trusted digital solutions and cybersecurity in health and care (CNECT)

Other actions (including prizes)

2020: Calls 1. and 2. and Other actions - only titles, no text

innovativeness! Trans-disciplinarity Open to any focus of diseases collaborations: public/private! emphasis on gender medicine when

relevant patient centred research/citizen Focus on impacts (ex. companies) Clinical studies ( up to fase 3) Ethical aspects 100% of funding rate for all

participants for R&I projects.

Important

Call 1 - Better Health and care, economic growth and sustainable health systems aims to achieve:

Develop sustainable health and care systems and growth opportunities for the health and care related industries;

Health and care systems and services more accessible, responsive and efficient

The scope of the call may range from : prevention, diagnosis, stratified approaches, predictive toxicology, novel and repurposed therapeutic approaches, including medical technologies and advanced therapies, cohorts and registries-based research, integration of care and systemic digital solutions for health and ageing well

Call 2 - Digital transformation in Health and Care aims to achieve: transformation of health and care services to more digitised, person-centred and community-based care models.

Maximize the potential of the digital economy in the health and care sectors 2 relevant priorities to the EC and to the European Cloud Initiative and the European Free Flow of Data Initiative The call will address eHealth, mobile health (mHealth) and Information and Communication Technologies (ICT) for Active and Healthy Ageing.

Call 3 - Trusted digital solutions and Cybersecurity in Health and Care aims to achieve: Cybersecurity to assure data privacy, security and protection of health and care infrastructures.

contribute to the following Focus Areas from WP ICT 2018-20: 'Digitising and transforming European industry and services' and 'Boosting the effectiveness of the Security Union‘. It addresses the need for secure and user-driven ICT-based solutions in early risk detection and interventions with big data approaches that enable aggregation of a variety of new and existing data sources such as medical records, registries, social platforms and other environmental, physiological and behavioural data, including data from large scale pilots on smart living environments.

Pubblicazione del Work Programme SC1 – 2018-2020 http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-health_en.pdf

Personalised Medicine in Work Programme 2018–2019

BHC-01-2019: Understanding causative mechanisms in co-and multimorbidities …DRUG- DRUG interaction

(SMEs participation strongly encouraged) (4-6 M euro per project)

BHC-03-2018: Exploiting research outcomes and application potential of the human microbiome for personalised prediction, prevention and treatment of disease (connected with SC 2, and IMI2 – HUMAN MICROBIOME)

10-15 M, SMEs encouraged.

BHC-04-2018: Rare Disease European Joint Programme Cofund (funding agencies) close link with IRDIRC http://www.irdirc.org ( public and private sector funders of research, patient advocacy groups, and scientific researchers to advance rare d.)

BHC-02-2019: Systems approaches for the discovery of combinatorial therapies for complex disorders - industry, SMEs participation strongly encouraged , excluded rare diseases

Scope:

understand at systems level the pathophysiology of a disorder in groups of patients responding well or poorly to particular therapies and further develop combinatorial therapies tailored to the needs of individuals or stratified patient groups

focus on already available and/or authorised therapies and have access to standardized biobank samples derived from retrospective or currently running clinical studies (late stage clinical trials is not within the scope of this topic)

invites proposals in complex disorders of high prevalence and of a high economic burden (rare diseases are excluded).

BHC-02-2019: Systems approaches for the

discovery of combinatorial therapies for complex

disorders

Impact:

New concepts of combinatorial therapies for complex disorders tailored to the needs of individuals or stratified patient groups.

Improved efficacy and take-up in the clinical setting in comparison to established therapeutic interventions.

Enable the development of personalised medicine.

Increased research & innovation opportunities in this industry intensive field, particularly for SMEs. Rare diseases are excluded).

BHC-02-2019: Systems approaches for the

discovery of combinatorial therapies for complex

disorders

Infectious diseases and improving global health in Work Programme 2018–2019 / I

• BHC-15-2018: New anti-infective agents for prevention and/or treatment of neglected infectious diseases (NID)

• BHC-16-2018: Global Alliance for Chronic Diseases (GACD) – Scaling up of evidence-based health interventions at population level for the prevention and management of hypertension and/or diabetes

• BHC-18-2018: Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC)

Scope:

• Should bridge the gap between preclinical and early clinical development of drugs and/or vaccines against neglected bacterial and parasitic diseases

• should focus on late preclinical (e.g. validation in animal models, toxicology, Good Manufacturing Practices (GMP) production, preparation of Investigational Medicinal Product Dossier) and early clinical (up to phase 1) development of already existing lead drug and vaccine candidates.

• include a clear pathway through the different necessary steps (research, manufacturing, regulatory approvals and licensing, IP management, pricing etc.) in order to allow uptake by health systems in limited-resource settings.

BHC-15-2018: New anti-infective agents for prevention and/or treatment of neglected infectious diseases (NID)

Expected Impact:

• Increase the number and quality of treatment and vaccine candidates for neglected infectious diseases appropriate for implementation and uptake by health systems with limited resources.

• Reduce the NIDs disease burden and their social and economic consequences, and thus contribute to achieving the United Nation's Sustainable Development Goals 1 (No Poverty), 3 (Good Health and Well-being), 5 (Gender Equality), 10 (Reduced Inequalities) and 13 (Climate Change).

• Strengthen the pipeline of products available to proceed into further development and clinical testing and, if appropriate, within the context of the European and Developing Countries Clinical Trials Partnership (EDCTP2). .

BHC-15-2018: New anti-infective agents for prevention and/or treatment of neglected infectious diseases (NID)

Tempi di pubblicazione, le scadenze, l’uso del single o doppio stage? Previsti bandi SINGLE STAGE e DOPPIO STAGE*

Call 2018 2019 2020

Opening Deadline Opening Deadline

1 Better Health and care, economic growth and sustainable health systems DG RTD

7 Nov 2017

6 Feb 2018* 4 Sett 2018*

26 Jul 2018

2 Oct 2018* 16 Apr 2019*

To be defined

18 Apr 2018 16 Apr 2019

2 Digital transformation in Health and Care DG Connect

7 Nov 2017 24 Apr 2018 26 Jul 2018 14 Nov 2018

16 Oct 2018 24 Apr 2019

3 Trusted digital solutions and Cybersecurity in Health and Care DG Connect

7 Nov 2017 24 Apr 2018 26 Jul 2018 14 Nov 2018

The contribution to Focus Areas will be EUR 186.50 million for 'Digitisation' and EUR 71 million for 'Security Union'.

*Other Actions excluded

445

100

36

504

107,5

60

490

150

25

0

100

200

300

400

500

600

Call - Better Health and care, economicgrowth and sustainable health systems

Call - Digital transformation in Health andCare

Call - Trusted digital solutions andCybersecurity in Health and Care

Budget (mill Eur)

Bandi SC1 2018-2019-2020*

48 topics (2018-2019) + 21 nel 2020 – senza considerare Other actions. ( 9 +7) Presenti RIA, IA, CSA, PCP, PPI, Era-Net, EJP

Presenti progetti di piccoli e grandi dimensioni (da 1,5 3, 6, 10, a 50 mill. Eur) Cooperazione internazionale maggiormente implementata attraverso Joint Calls

(CELAC, Russia, China, Canada) e in aree di rilevante interesse per EU: human data on personalized medicine approaches with Canada non-communicable diseases CELAC HIV, tuberculosis and/or hepatitis C with Russia Strategic collaboration on healthcare R&I with China

0

5

10

15

20

2524

17

3 1 1 1 1

No. of topics vs Funding scheme

SC1 and international cooperation

Mutual opening of research programmes with Third Countries (USA)

Funding of Third Countries entities by their own funding agencies for participating to Horizon 2020 (Switzerland, Australia, etc)

Specific actions

Strategic Initiatives around HEALTH

Innovative Medicines Initiative 2 www.imi.europa.eu

European & Developing Countries Clinical Trials Partnership (EDCTP2)

www.edctp.org Active and Assisted Living 2

www.aal-europe.eu

European Innovation Partnership on Active and Healthy Ageing https://webgate.ec.europa.eu/eipaha

34

IMI 2 budget

€3.276 bn

Partnership 2014 - 2024

€1.638 bn

€1.638 bn

+ other Companies*

EFPIA = European Federation of Pharmaceutical Industries and Associations

* Imaging, Diagnostics, IT for health etc.

The IMI portfolio

Strategic Research Agenda

Antimicrobial resistance

Osteoarthritis

Cardiovascular diseases

Diabetes/Metabolic disorders

Neurodegenerative diseases

Psychiatric diseases

Respiratory diseases

Immune-mediated diseases

Ageing-associated diseases

Cancer

Rare/Orphan Diseases

Vaccines

Private

Investment

in kind

(€ 1 billion)

EU Public

Funding

cash

(€ 1 billion)

EFPIA

ACADEMIA

HOSPITALS

PATIENTS’ ORGANISATIONS

SMALL AND MEDIUM-SIZED ENTERPRISES

REGULATORS

Pharma

1

Pharma

2

Pharma

3

Pharma

4

Pharma

5

Pharma

6

A Typical IMI Consortium

Academic institutions

Small & medium-sized enterprises (SMEs)

Mid-sized enterprises (≤ €500m)

Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:

EU Member States

Associated Countries

At least three legal entities

Who is eligible for funding?

Other countries: No funding unless - participation deemed essential by IMI for

carrying out the action - Annual Work Plan / Calls documents

New!

IMI partner search tool: https://cloud.imi.europa.eu/web/eimi-pst

IMI 2 – Call 8 includes the following topic:

Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks The indicative budget for the entire period of 2 years is €70 million.

Topics for IMI Call 13: http://www.imi.europa.eu/apply-funding/open-calls/imi2-call-13

Topic 1: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches Topic 2: Genome-Environment Interactions in Inflammatory Skin Disease Topic 3: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use Topic 4: Mitochondrial Dysfunction in Neurodegeneration Topic 5: Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative Topic 6: A sustainable European induced pluripotent stem cell platform Topic 7: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice Topic 8: Human tumour microenvironment immunoprofiling Topic 9: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now Topic 10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system Topic 11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease Topic 12: Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes Topic 13: Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases Topic 14: Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases Topic 15: Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases

Interested in applying? Read our tips for applicants and advice on finding project partners

Stay in touch

Visit our website

www.imi.europa.eu

Sign up to our newsletter

bit.ly/IMInewsletter

Follow us on Twitter

@IMI_JU

Join our LinkedIn group

bit.ly/LinkedInIMI

E-mail us

infodesk@imi.europa.eu

DG SANTE Third Health Programme 2014-2020

43

Il programma si concentra su quattro obiettivi principali, il cui scopo è conseguire un forte potenziale di crescita economica grazie al miglior stato di salute:

1) Sviluppare strumenti e meccanismi comuni a livello dell'UE per affrontare la carenza di risorse umane e finanziarie, al fine di contribuire a sistemi sanitari innovativi e sostenibili;

2) Migliorare l'accesso alle competenze mediche e alle informazioni concernenti patologie specifiche anche su scala transnazionale e sviluppare soluzioni condivise e orientamenti per migliorare la qualità della sanità e della sicurezza dei pazienti.

3) Individuare, diffondere e promuovere l'adozione di buone pratiche convalidate per prevenire le malattie e promuovere la buona salute.

4) Sviluppare approcci comuni per proteggere i cittadini dalle minacce sanitarie transfrontaliere.

http://ec.europa.eu/health/programme/policy/index_en.htm 44

45

Deadline della pre-proposal 6 marzo 2018

Esempio prossimo bando 2018

"Multinational research projects on Health and Social Care for Neurodegenerative

Diseases“

Sulle aree:

• Care pathways and services using the potential of patient involvement

• Factors influencing progression and prognosis of disease

• Outcome measures for patients and their informal carers

• Palliative care of patients

• Cost-effectiveness and affordability of interventions including ethical concerns

Submission deadline for pre-proposals: March 6, 2018, 23:59h C.E.T. http://www.neurodegenerationresearch.eu/wp-content/uploads/2018/01/JPND-HSC-Call-Text-2018.pdf Per l’Italia: solo IRCCs ammessi.

La partecipazione è aperta ad una vasta gamma di organizzazioni, tra cui: Gli Istituti di Ricerca , Università e Ospedali Gli enti pubblici ONG Imprese Commerciali

CHI NE BENEFICIERÀ E COME

Direttamente: tutte le amministrazioni pubbliche nazionali ed europee attive nell'assistenza sanitaria, e gli organismi privati, le ONG e i gruppi di interesse che promuovono politiche e sistemi sanitari più adatti alle attuali sfide demografiche e sociali.

Indirettamente: tutti gli europei, grazie a una migliore assistenza sanitaria, alla promozione della salute e a misure di prevenzione.

Le dotazioni finanziarie per l'attuazione del programma per il periodo dal 1° gennaio 2014 al 31 dicembre 2020 ammonteranno a 449,4 milioni di EUR.

46

The EU grant is limited to a maximum co-funding rate of 60% of eligible costs. In case of exceptional utility up to 80% can be granted

Come partecipare? Vi interessa partecipare al programma per la salute? Tutte le informazioni, insieme al modulo di candidatura, sono disponibili qui: Agenzia Esecutiva per i Consumatori, Salute, Agricoltura e Alimentazione - CHAFEA

Il referente nel nostro paese Contattate il referente nel vostro paese per ottenere assistenza e consigli: Punto focale nazionale Dr Giovanni NICOLETTI Ministero della Salute nfp_eahc@sanita.it

Per ulteriori informazioni : http://ec.europa.eu/chafea/health/index.html Database progetti finanziati: http://ec.europa.eu/chafea/projects/database.html 47

48

La strategia del JPND rappresenta una visione per coordinare la ricerca nell'ambito delle malattie neurodegenerative, in particolare l'Alzheimer. Si affronta l'intero spettro di attività di ricerca che è necessario per affrontare il peso crescente di queste patologie per il prossimo decennio e oltre. L'obiettivo del Programma Congiunto (JPND)* è quello di migliorare rapidamente la nostra comprensione delle cause di questo tipo di malattie. Oltre a fornire ai medici gli strumenti per diagnosticare e trattare queste malattie sin dalla fase precoce, il JPND dovrebbe anche portare ad un migliore sistema di assistenza sanitaria e sociale sia per i pazienti che per chi si prende cura di loro.

*The JPND diseases are: Alzheimer’s disease (AD) and other dementias, Parkinson’s disease (PD) and PD related disorders, Prion disease, Motor neurone diseases (MND), Huntington’s Disease (HD), Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA)

49

Implementation Plan A first-phase JPND Implementation Plan has been agreed for the period of 2012-2014. The plan has these major action areas: Annual Calls for Proposals Action Groups to determine research needs and opportunities Action Groups to promote engagement, commitment and partnerships Annual Calls for Proposals JPND intends to launch Calls for proposals each year to address high priority areas in neurodegenerative disease research. Over the period of 2012-2014, it is anticipated that JPND will launch calls to address each of the following priority areas: http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/open-calls/

NEW Partnering Tool http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/partnering-tool/

50

In general: Minimum 3 and maximum of 6 research groups (principal investigators) from at least 3 different

countries of the funding organizations participating in this call

JPND website http://www.neurodegenerationresearch.eu/home/ secretariat@jpnd.eu

Per ulteriori informazioni: Adriana Maggi, Ph.D. Member of the JPND Management Board Director Center of Excellence on Neurodegenerative Diseases University of Milan adriana.maggi@unimi.it

51

52

I settori d'intervento prioritari sono stati individuati nel piano strategico di attuazione e nel piano operativo, adottati nel 2011 dal gruppo direttivo incaricato dell'avvio e dell'attuazione della partnership. Per realizzare il piano tutti i soggetti interessati hanno iniziato a collaborare nell'ambito di gruppi d'azione. Action Group A1: Prescription and adherence action at regional level. Action Group A2: Personalized health management: Falls prevention. Action Group A3: Prevention of functional decline and frailty. Action Group B3: Integrated care for chronic diseases, including remote monitoring at regional level. Action Group C2: Interoperable independent living solutions. Action Group D4: Age friendly buildings, cities and environments.

Stakeholders wishing to get involved in the advancing of Specific Actions have formed Action Groups through the "Invitation for Commitment" application process. In each Action Group, stakeholders commit to running a number of activities, contributing towards the headline target, starting with the creation and implementation of an Action Plan.

53

54

55

E-Rare-3 ERA-NET rare disease research implementing

IRDiRC objectives AGENCE NATIONALE DE LA

RECHERCHE FR

ERACoSysMed

ERACoSysMed - Collaboration on systems medicine funding to promote the implementation of systems biology approaches in clinical research

and medical practice

FORSCHUNGSZENTRUM JUELICH GMBH

DE

JPco-fuND ERA-NET for establishing synergies between the

Joint Programming on Neurodegenerative Diseases Research and Horizon 2020

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

(INSERM) FR

TRANSCAN-2 ERA-NET: Aligning national/regional translational

cancer research programmes and activities MINISTERO DELLA SALUTE IT

ERA-Nets finanziate in Horizon 2020 con partecipazione italiana

ERA-CVD ERA-NET on cardiovascular diseases to implement

joint transnational research projects and set up international cooperations

DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV

DE

JPI-EC-AMR ERA-NET for establishing synergies between the Joint Programming Initiative on Antimicrobial

Resistance Research and Horizon 2020

VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL

SE

NEURON Cofund ERA NET NEURON in the area of brain-related diseases and disorders of the nervous system

DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV

DE

LINK UTILI

H2020 Participant portal: http://ec.europa.eu/research/participants/portal/desktop/en/home.html Partner search https://ec.europa.eu/research/participants/portal/desktop/en/organisations/partner_search.html Risultati dei progetti: http://ec.europa.eu/research/participants/portal/desktop/en/projectresults/index.html EMA: European Medicine Agency http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/11/WC500217406.pdf

Grazie per l’attenzione

APRE Agenzia per la Promozione della Ricerca Europea

via Cavour, 71 00184 - Roma

www.apre.it Tel. (+39) 06-48939993 Fax. (+39) 06-48902550

Caterina BUONOCORE buonocore@apre.it

Health NCP

57